A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Published data in a leading medical journal shows that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month after stopping.
"People buying such medications must be informed of the risk of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain suggests a return to original mass in about one and a half years.
Analyzing Therapies
The research, which examined 37 of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.
Scientists note that people who lose weight through dieting usually see a slower weight regain—around 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Nutrition scientists believe the way of the injections is key to understanding the amplified regain.
These medications mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
The NHS suggest the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, considering the high risk of weight regain, the therapy is often life-long.
This view is echoed by drug manufacturers, who say that the findings "underscore the long-term character of excess weight," akin to managing conditions like high blood pressure.
User Testimonies
Individuals who have stopped the medication explain a sudden return of cravings.
"It was like a trigger that goes on and I was suddenly starving," recalled one woman.
The struggle is compounded if patients have not adopted permanent dietary or behavioural changes during therapy.
Growing Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the past year, with desire continuing to grow.
- Use is greater among females compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and maintained weight loss hinges on integrated behavioural changes.
